Baseline characteristics of patients with and without hypercoaguable sepsis and the effect of afelimomab on mortality: a post hoc analysis from the MONARCS trial
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Tumor necrosis factor (TNF)α may modulate clot-promoting and inhibiting pathways,
and have potentially important roles in disseminated intravascular coagulation (DIC).
Purpose
1) To determine if differences in baseline characteristics exist between patients
with and without hypercoaguable sepsis, and 2) to explore the effect of afelimomab
(an anti-TNFα antibody) on mortality of hypercoaguable and non-hypercoaguable septic
patients.
Methods
A post hoc analysis identified patients with a hypercoaguable state in the overall
population enrolled in a large placebo-controlled sepsis trial investigating the safety
and efficacy of afelimomab. A hypercoaguable state was defined by (1) platelet count
below 140,000 per μl plus (2) D-dimer > 250 ng/ml. Patients were randomized to receive
placebo or afelimomab.
Results
A total of 2634 patients were enrolled, and 1313 (49.8%) had baseline determinations
of both platelets and D-dimer. The table describes the baseline characteristics of
the two patient groups. Compared to those without laboratory evidence of consumption
coagulopathy, patients with a hypercoagulable state had higher organ dysfunction scores,
higher interleukin-6 levels and higher frequencies of positive blood cultures. Among
the patients with evidence of consumption coagulopathy, 283 were treated with placebo
and 311 with afelimomab. Mortality at 28 days was 43.8% vs 38.6% in placebo and afelimomab
patients, respectively. In patients not meeting the definition of hypercoaguability,
376 and 343 received placebo and afelimomab; mortality was 35.9% and 26.5%, respectively.
Table
Absence of
Hypercoaguable
hypercoaguable
state
state
(n = 594)
(n = 719)
Mean age (SD)
57.9 (17.0)
60.1 (17.0)
Gender (M/F)
58.6% / 41.4%
61.6% / 38.4%
Shock
399 (67.2%)
504 (70.1%)
MOD score
9.1
6.3
Median interleukin-6 (pg/ml)
1360
908
Mean platelet count × 1000 (SD)
81.7 (35.6)
231.4 (141.7)
Positive blood culture (%)
278 (46.8%)
226 (31.4%)
G (+) bacteria only (%)
185 (31.1%)
207 (28.8%)
G (–) bacteria only (%)
169 (28.5%)
177 (24.6%)
Mixed G (+) and G (–) (%)
65 (10.9%)
102 (14.2%)
Other or unknown (%)
175 (29.5%)
233 (32.4%)
Conclusions
Septic patients with evidence of consumption coagulopathy had more organ dysfunction
and a higher rate of positive blood cultures. Afelimomab appears to be beneficial
in reducing the mortality of septic patients with a hypercoaguable state.